The Risk of Psychiatric Disorders in Finasteride Users With Benign Prostatic Hyperplasia and Androgenetic Alopecia: A Population-Based Case-Control Study

    November 2024 in “ Australasian Journal of Dermatology ”
    Keng Chen, Samuel Zagarella
    Image of study
    TLDR The study's methods are flawed, making its conclusions about finasteride and mental health unreliable.
    The document critiques a study on the risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA), highlighting methodological issues. It argues that the study is mislabelled as a case-control study when it is actually a retrospective cohort study, leading to potential confusion and misinterpretation of results. The study's control group, which lacks AGA, introduces confounding factors, making it difficult to attribute mental health outcomes solely to finasteride use. The critique emphasizes the importance of accurately reporting study methodologies to ensure reliable conclusions and facilitate future research.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 1000+ results

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 2 years ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

      community If you’re on the fence about Finasteride, don’t wait!

      in Finasteride/Dutasteride  78 upvotes 3 years ago
      Finasteride, a medication for hair loss that has both positive and negative effects. Users discussed their own personal experiences with the drug as well as potential side-effects of taking it, such as erectile dysfunction or gynecomastia. Suggestions were also made about starting at a lower dosage to minimize these risks.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      by nkrata in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Dermatologist told me to quit fin after turning 40

      in Finasteride/Dutasteride  194 upvotes 2 years ago
      A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.

    Related Research

    1 / 1 results